Bullish Views for XPeng and Blueprint Medicines
- August 21st, 2023
- 466 views
XPeng Inc. (NYSE: XPEV), a leading Chinese electric vehicle manufacturer, received a boost in investor sentiment as BofA Securities upgraded the company from Neutral to Buy and raised the price target from $16.30 to $22.00.
Considering that $XPEV closed at $14.98 on Friday, the adjusted price target indicates a potential upside of $7.02 or approximately 46.83%, based on the financial advisory firm's assessment
In other news, Blueprint Medicines Corporation (Nasdaq: BPMC) continues to receive a favorable evaluation from Needham, as the brokerage firm maintained its Buy rating and raised the price target from $65 to $66.
Based on Friday's closing price of $49.29, the updated price target implies a potential upside of $16.71 or approximately 33.88% for $BPMC, according to Needham's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login